Drug Utilization Review Board Meeting Materials

Drug Utilization Review Board Meeting Materials

Meeting information is retained on this page for 7 years then sent to the Missouri State Archives.

Register for Public Comment

Any interested party shall be granted the opportunity for clinically relevant public comment for up to five (5) minutes per medication under review by the DUR Board. The responsibility of scheduling the presentation shall rest with the interested party. Interested parties representing a manufacturer shall be granted five (5) minutes in the aggregate per medication under review by the DUR Board.

   Register

2024

April 17, 2024

DUR Agenda April 2024
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Givlaari April 2024
Imcivree April 2024
Megestrol Acetate April 2024
Nulibry April 2024
Scenesse April 2024
Spravato April 2024
Zokinvy April 2024
DUR Criteria
Clinical and Fiscal Edits- New or Revised of Existing Criteria
Media
Acne or Rosacea Select Topical April 2024
Antifungals Systemic April 2024
Fabry Disease April 2024
GABAA Modulators for PPD April 2024
Isturisa April 2024
Oxervate April 2024
Pompe Disease April 2024
Prior Auth Required Fiscal Edit April 2024
Voxzogo April 2024
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents, Topical April 2024
Androgenic Agents April 2024
Antibiotics, Inhaled April 2024
Anticholinergics, Long Acting Beta Adrenergic (LABA) Combinations April 2024
Anticholinergics, Short Acting and Combinations Inhaled April 2024
Antifungals (Onychomycosis/Candidiasis), Oral April 2024
Antifungals, Topical April 2024
Antihistamines and Antihistamine/Decongestant Combinations, 2nd Generation April 2024
Antihistamines, Intranasal April 2024
Antihistamines, Ophthalmic April 2024
Antiparasitics, Topical April 2024
Antivirals, Herpes Oral April 2024
Antivirals, Topical April 2024
Beta Adrenergic, Long Acting April 2024
Beta Adrenergic, Nebulized April 2024
Corticosteroids, Ophthalmic “Soft” April 2024
Corticosteroids, Topical April 2024
Fluoroquinolones, Ophthalmic April 2024
Leukotriene Receptor Modifiers April 2024
Mast Cell Stabilizers, Ophthalmic April 2024
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Ophthalmic April 2024
Pancreatic Enzyme Agents April 2024
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticholinergics, Long Acting Beta Adrenergics (LABA)/ Inhaled Corticosteroid (ICS) Combinations and Phosphodiesterase 4 (PDE4) Inhibitors April 2024
Anticholinergics, Long Acting Inhaled April 2024
Benzoyl Peroxide/Antibiotic Combinations April 2024
Beta Adrenergic Agents, Short Acting April 2024
Corticosteroids & Rhinitis Agents, Intranasal April 2024
Corticosteroids, Oral Inhaled April 2024
Cough and Cold Preparations April 2024
Epinephrine Agents, Self-Injectable April 2024
Fluoroquinolones, Otic April 2024
Gene Therapies for Sickle Cell Disease and Beta-Thalassemia April 2024
Glaucoma Agents April 2024
Hepatitis C Agents April 2024
Inflammatory Bowel Disease Agents, Oral April 2024
Inflammatory Bowel Disease Agents, Rectal April 2024
Retinoids, Topical April 2024

January 17, 2024

DUR Agenda January 2024
DUR Minutes January 2024 Draft
DUR Criteria
Clinical and Fiscal Edits- Existing Criteria
Media
Benzodiazepine (Select Oral) January 2024
Butalbital Combinations without Codeine January 2024
Camzyos January 2024
Corlanor January 2024
Empaveli January 2024
Enjaymo January 2024
HBV Nucleotide Analog Reverse Transcriptase Inhibitors January 2024
High Risk Therapies January 2024
Morphine Milligram Equivalent Accumulation January 2024
Non-Oral Contraceptives January 2024
Selzentry January 2024
Skysona January 2024
Tavneos January 2024
Transmucosal Immediate Release Fentanyl (TIRF) January 2024
Verquvo January 2024
Zynteglo January 2024
DUR Criteria
Clinical and Fiscal Edits- New or Revised of Existing Criteria
Media
Anti-Amyloid Monoclonal Antibody January 2024
Antipsychotics - 1st Generation (Typical) January 2024
Auvelity January 2024
C5 Complement Inhibitors January 2024
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators January 2024
Duchenne Muscular Dystrophy (DMD) January 2024
Hemophilia Gene Therapy Agents January 2024
Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) Stabilizers January 2024
Opioids – Short-Acting January 2024
Sohonos January 2024
Ztalmy January 2024
DUR Criteria
Resource List - New or Revised Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Depot Agents January 2024
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents January 2024
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations January 2024
Antibiotics, Mupirocin Topical January 2024
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists January 2024
Anti-Parkinsonism, MAO-B Inhibitors January 2024
Anti-Parkinsonism, Non-Ergot Dopamine Agonists January 2024
Calcitonin Gene-Related Peptide (CGRP) Inhibitors January 2024
Cephalosporin Agents January 2024
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors January 2024
Fluoroquinolones, Oral January 2024
Hereditary Angioedema Agents January 2024
Macrolides January 2024
NSAIDs January 2024
Opioids, Long Acting January 2024
Penicillin Agents January 2024
Somatostatin Analogs January 2024
Tetracyclines January 2024
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Antiandrogenic Agents January 2024
Antibiotics, Gastrointestinal (GI) January 2024
Antibiotics, Vaginal January 2024
Anticonvulsants, Dravet Syndrome January 2024
Antiemetics, 5-HT3 and NK1 Injectables January 2024
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables January 2024
Anti-Migraine, Alternative Agents January 2024
Antiretroviral Therapy (ART) January 2024
Fibromyalgia Agents January 2024
GI Motility Agents, Chronic January 2024
Glucagon Agents January 2024
Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) January 2024
Neuropathic Pain Agents January 2024
Opioid & Select Alcohol Dependence Agents January 2024
Opioid Emergency Reversal Agents January 2024
Sedative Hypnotics January 2024
Skeletal Muscle Relaxants January 2024
Systemic Enzyme Inhibitors, FGFR Inhibitors January 2024
Tramadol-Like Agents January 2024
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors January 2024

2023

October 18, 2023

DUR Agenda October 2023
DUR Minutes January 2023 Approved
DUR Criteria
Old Business
Media
Neuromyelitis Optica Spectrum Disorder October 2023
C5 Complement Inhibitors October 2023
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Alpelisib October 2023
Emsam October 2023
Entresto October 2023
Immunoglobulins IVIG and SCIG October 2023
Narcolepsy Inhibitors October 2023
Nuedexta October 2023
Palforzia October 2023
Parathyroid Hormone and Bone Resorption Suppression Related Agents October 2023
Sickle Cell Disease October 2023
Spinal Muscular Atrophy October 2023
SSRI Step Therapy October 2023
Transthyretin Mediated Amyloidosis ATTR October 2023
Xcopri October 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Botulinum Toxin October 2023
Diagnosis Code Required Policy October 2023
Enzyme Deficiency Select Agents October 2023
Generalized Myasthenia Gravis October 2023
Lambert Eaton Myasthenic Syndrome October 2023
Psychotropic Medications Polypharmacy October 2023
Ranolazine October 2023
RSV Prophylaxis Pediatric October 2023
Skyclarys October 2023
SNRI October 2023
Vyjuvek October 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
ACE Inhibitors CCB Combinations October 2023
ADHD Amphetamines Short Acting October 2023
ADHD Methylphenidate Short Acting October 2023
ADHD Non Stimulants October 2023
ARB CCB Combo October 2023
Anticonvulsants Rescue Agents October 2023
Antiplatelet Agents October 2023
BAB And Diuretic Combos October 2023
Bone Ossification Agents October 2023
CCBs Dihydropyridine October 2023
Direct Renin Inhibitors and Combos October 2023
Electrolyte Depleting Agents Phosphate Lowering October 2023
Niacin Derivatives October 2023
Niacin Derivatives October 2023
PCSK9 Inhibitors October 2023
PAH Agents ETRAs October 2023
PAH Agents PPAs Inhaled October 2023
PAH Agents PPAs Injectable October 2023
PAH Agents PPAs Oral October 2023
Triglyceride Lowering Agents October 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
ACE Inhibitors Diuretic Combos October 2023
ADHD Amphetamines Long Acting October 2023
ADHD Methylphenidate Long Acting October 2023
ARBs and ARB Diuretic Combos October 2023
Anticoagulants, Oral and Subcutaneous October 2022
Antihyperuricemic Agents October 2023
Benign Prostatic Hyperplasia Agents October 2023
Beta Adrenergic Agents Short Acting October 2023
Bile Salt Agents October 2023
CCBs Non Dihydropyridine October 2023
Electrolyte Depleting Agents Potassium Lowering October 2023
HoFH Agents October 2023
Keratoconjunctivitis Agents October 2023
Mineralocorticoid Receptor Antagonists October 2023
Proton Pump Inhibitors October 2023
PAH Agents PDE5 and SGC Stimulators October 2023
Statins HMG CoA Reductase Inhibitors and Combos October 2023
Sympatholytics October 2022
Urea Cycle Disorder Agents October 2023

July 20, 2023

Agenda 7-20-23
DUR Minutes July 2023 Approved
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
AMPYRA July 2023
Besremi July 2023
C5 Complement Inhibitors July 2023
CAR-T Cell July 2023
Crysvita July 2023
DMD July 2023
Gamifant July 2023
Iron – Injectable July 2023
Koselugo July 2023
Luxturna July 2023
NMOSD July 2023
Reblozyl July 2023
TIMS, Small Molecule JAK Inhibitor July 2023
Tolvaptan July 2023
Vyvgart July 2023
Zometa July 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
DAYBUE July 2023
Enjaymo July 2023
Filspari July 2023
Givlaari July 2023
Joenja July 2023
Synagis July 2023
Tepezza July 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Alpha Glucosidase Inhibitors July 2023
Amylin Analogs July 2023
Biguanides & Combination Agents July 2023
Cryopyrin-Associated Periodic Syndrome (CAPS) July 2023
DPPIV Inhibitors July 2023
Erythropoiesis Stimulating Agents July 2023
GLP-1s and Combination Agents July 2023
Insulin, Mixed July 2023
Insulin, Non-Analogs July 2023
Insulin, Rapid Acting July 2023
LHRH, GnRH Agents, Oral July 2023
Meglitinides July 2023
Methotrexate Agents July 2023
Psoriasis Agents, Oral July 2023
Sulfonylurea Agents, 2nd Generation July 2023
Thiazolidinediones & Combos July 2023
TIMs, IL17 Receptor Antagonists July 2023
TIMs, IL23-12 Inhibitors July 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Atopic Dermatitis Agents, Immunomodulators July 2023
Bleeding Disorder Agents July 2023
Colony Stimulating Factors July 2023
Growth Hormone Agents, Somatropin July 2023
Growth Hormone Releasing Factors, Select Agents July 2023
Insulin, Long Acting July 2023
LHRH, GnRH Agents, Non-Oral July 2023
Multiple Sclerosis Agents, Injectable July 2023
Multiple Sclerosis Agents, Oral July 2023
Psoriasis Agents, Topical July 2023
SGLT Inhibitors July 2023
Thrombocytopenia Agents July 2023
TIMs, IL6 Receptor Inhibitors July 2023
TIMs, JAK Inhibitors July 2023
TIMs, Misc Allergy & Asthma Related Monoclonal Antibodies July 2023
TIMs, Select Agents July 2023
TIMs, Select Agents July 2023
Urinary Tract Antispasmodics July 2023

April 20, 2023

DUR Agenda April 2023
DUR Minutes April 2023
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Acne and Rosacea – Select Topical Agents Step Therapy Edit April 2023
Fabry Disease April 2023
Givlaari April 2023
Imcivree April 2023
Isturisa April 2023
Megestrol Acetate April 2023
Nulibry April 2023
Oxervate April 2023
Oxlumo April 2023
Scenesse April 2023
Sickle Cell Disease April 2023
Spravato April 2023
Systemic Antifungals April 2023
Tavneos April 2023
Voxzogo April 2023
Zulresso April 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Hemgenix April 2023
Tzield April 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents, Topical April 2023
Androgenic Agents April 2023
Antibiotics, Inhaled April 2023
Anticholinergics, LABA Combo, Short Acting and Combo Inhaled April 2023
Antihistamines and Antihistamine/Decongestant Combinations, 2nd Generation April 2023
Antihistamines, Intranasal April 2023
Antiparasitics, Topical April 2023
Antivirals, Herpes Oral April 2023
Benzoyl Peroxide/Antibiotic Combinations April 2023
Beta Adrenergic Agents, Nebulized April 2023
Beta Adrenergic Agents, Short Acting April 2023
Corticosteroids, Ophthalmic “Soft” April 2023
Corticosteroids, Oral Inhaled April 2023
Corticosteroids, Topical April 2023
Cough and Cold Preparations April 2023
Fluoroquinolones, Ophthalmic April 2023
Fluoroquinolones, Otic April 2023
Hepatitis C Agents April 2023
Leukotriene Receptor Modifiers April 2023
Mast Cell Stabilizers, Ophthalmic April 2023
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Ophthalmic April 2023
Pancreatic Enzyme Agents April 2023
Retinoids, Topical April 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors April 2023
Anticholinergics, Long Acting Inhaled April 2023
Antifungals, Oral April 2023
Antihistamines, Ophthalmic April 2023
Antivirals, Topical April 2023
Beta Adrenergic Agents, Long Acting April 2023
Corticosteroids & Rhinitis Agents, Intranasal April 2023
Epinephrine Agents, Self-Injectable April 2023
Glaucoma Agents April 2023
Inflammatory Bowel Disease Agents, Oral April 2023
Inflammatory Bowel Disease Agents, Rectal April 2023

January 18, 2023

DUR Agenda January 2023
DUR Minutes January 2023
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Aduhelm Clinical Edit January 2023
Antipsychotics - 1st Generation (Typical) Clinical Edit January 2023
Benzodiazepines (Select Oral) Clinical Edit January 2023
Butalbital Combinations without Codeine Clinical Edit January 2023
Corlanor Clinical Edit January 2023
Empaveli Clinical Edit January 2023
HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit January 2023
High Risk Therapies Clinical Edit January 2023
Kerendia Clinical Edit January 2023
Morphine Milligram Equivalent Accumulation Clinical Edit January 2023
Non-Oral Contraceptives Fiscal Edit January 2023
Oxazolidinone Fiscal Edit January 2023
Pompe Disease Clinical Edit January 2023
Selzentry Clinical Edit January 2023
Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit January 2023
Verquvo Clinical Edit January 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Camzyos™ Clinical Edit January 2023
CFTR Modulators Clinical Edit January 2023
Opioids – Short-Acting Clinical Edit January 2023
Skysona Clinical Edit January 2023
Xenpozyme Clinical Edit January 2023
Zynteglo Clinical Edit January 2023
DUR Criteria
Review List Edit - New or Revised Criteria
Media
Antipsychotics - 2nd Generation (Atypical) Depot Agents Resource List January 2023
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents Resource List January 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit January 2023
Antiemetics, 5-HT3 and NK1 Injectables PDL Edit January 2023
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit January 2023
Antiplatelet Agents PDL Edit January 2023
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit January 2023
Anti-Parkinsonism, MAO-B Inhibitors PDL Edit January 2023
Anti-Parkinsonism Non-Ergot Dopamine Agonists PDL Edit January 2023
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit January 2023
Glucagon Agents PDL Edit January 2023
Hereditary Angioedema Agents PDL Edit January 2023
NSAIDs PDL Edit January 2023
Opioid Emergency Reversal Agents PDL Edit January 2023
Somatostatin Analogs PDL Edit January 2023
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit January 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticonvulsants, Dravet Syndrome PDL Edit January 2023
Anti-Migraine, Alternative Oral Agents PDL Edit January 2023
Antiandrogenic Agents PDL Edit January 2023
Antiretroviral Therapy (ART) PDL Edit January 2023
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit January 2023
Fibromyalgia Agents PDL Edit January 2023
GI Motility Agents, Chronic PDL Edit January 2023
Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit January 2023
Neuropathic Pain Agents PDL Edit January 2023
Opioid and Select Alcohol Dependence Agents PDL Edit January 2023
Sedative Hypnotics PDL Edit January 2023
Skeletal Muscle Relaxants PDL Edit January 2023
Tramadol-Like Agents PDL Edit January 2023

2022

October 19, 2022

DUR Agenda October 2022
DUR Minutes October 2022
DUR Criteria
Conduent Reports
Media
Conduent Reports October 2022
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Entresto October 2022
SMA October 2022
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Alpelisib October 2022
ATTR October 2022
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
ACEI_ACEI-Diuretic Combinations October 2022
ACEI_CCB Combinations October 2022
ADHD, Methylphenidate SA October 2022
ADHD, Non-Stimulants October 2022
Alpha Glucosidase Inhibitors October 2022
Amylin Analogs October 2022
Antibiotics, Mupirocin Topical October 2022
Antihyperuricemic Agents October 2022
ARB_ARB-Diuretic Combos October 2022
ARB-CCB Combos October 2022
BB_BB-Diuretic Combos October 2022
Benign Prostatic Hyperplasia (BPH) Agents October 2022
Biguanides and Combination Agents October 2022
Bone Ossification Agents October 2022
CCB, Non-DHP October 2022
Cephalosporins October 2022
Direct Renin Inhibitors and Combos October 2022
DPPIV Inhibitors October 2022
Electrolyte Depleting Agents, Phosphate Lowering October 2022
Fluoroquinolones, Oral October 2022
Homozygous Familial Hypercholesterolemia (HoFH) October 2022
Insulin, Mixed October 2022
Insulin, Non-Analogs October 2022
Insulin, Rapid Acting October 2022
Macrolides October 2022
Methotrexate Agents October 2022
Niacin Derivatives October 2022
PAH, ETRAs October 2022
PAH, PDE5-SGC October 2022
PAH, Prostacyclins Oral October 2022
Penicillins October 2022
SGLT2 Inhibitors October 2022
Statins and Combos October 2022
Sulfonylurea Agents, Second Generation October 2022
Tetracyclines October 2022
Thiazolidinediones and Combinations October 2022
Thrombocytopenia Agents October 2022
Triglyceride Lowering Agents October 2022
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
ADHD, Amphetamines Long Acting October 2022
ADHD, Amphetamines Short Acting October 2022
ADHD, Methylphenidate Long Acting October 2022
Antibiotics, GI Oral October 2022
Antibiotics, Vaginal October 2022
Anticoagulants, Oral and Subcutaneous October 2022
Anticonvulsants, Rescue Agents October 2022
Bile Salt Agents October 2022
CCB, DHP October 2022
Colony Stimulating Factors October 2022
Cryopyrin-Associated Periodic Syndrome (CAPS) October 2022
Dry Eye Disease Agents October 2022
Electrolyte Depleting Agents, Potassium Lowering October 2022
Erythropoiesis Stimulating Agents October 2022
GLP-1 Receptor Agonists and Combination Agents October 2022
Growth Hormone Agents, Somatropin October 2022
Growth Hormone and Growth Hormone Releasing Factors, Select Agents October 2022
Insulin, Long Acting October 2022
LHRH, GnRH Agents, Non-Oral October 2022
LHRH, GnRH Agents, Oral October 2022
Multiple Sclerosis Agents, Injectable October 2022
PAH, Prostacyclins Inhaled October 2022
PAH, Prostacyclins Injectable October 2022
PCSK9 Inhibitor October 2022
Proton Pump Inhibitors (PPIs) October 2022
Sympatholytics October 2022
Targeted Immune Modulators JAK Inhibitors October 2022
Targeted Immune Modulators, IL6 Receptor Inhibitors October 2022
Targeted Immune Modulators, IL17 Receptor Antagonists October 2022
Targeted Immune Modulators, IL23-12 Inhibitors October 2022
Targeted Immune Modulators, Misc Allergy and Asthma Related Monoclonal Antibodies October 2022
Targeted Immune Modulators, Select Agents October 2022
Targeted Immune Modulators, TNF Inhibitors October 2022
Urinary Tract Antispasmodics September 2022

July 20, 2022

DUR Agenda July 2022
DUR Minutes July 2022
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Ampyra June 2022
ATTR June 2022
Botulinum Toxin June 2022
DMD June 2022
Emsam June 2022
Gamifant June 2022
Immunoglobulin June 2022
Koselugo June 2022
Luxturna June 2022
Luxturna June 2022
Narcolepsy Inhibitors June 2022
NMOSD June 2022
Nuedexta June 2022
Oxandrin June 2022
Palforzia June 2022
Palynziq June 2022
Ranexa June 2022
Reblozyl June 2022
SSRI June 2022
Synagis June 2022
Tepezza June 2022
Tolvaptan June 2022
Xcopri June 2022
Zometa June 2022
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Besremi June 2022
CAR T Cell June 2022
Crysvita June 2022
Enjaymo June 2022
Enzyme Deficiency Select Agents June 2022
Iron Injectable June 2022
LEMS June 2022
Manufacturers Requiring PA June 2022
PolyPharm June 2022
PTH and Other Agents June 2022
SNRI June 2022
TIMS Small Molecule JAK Inhibitor June 2022
Vyvgart June 2022

April 20, 2022

DUR Agenda April 2022
DUR Minutes April 2022
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Imcivree March 2022
Megestrol Acetate March 2022
Nulibry March 2022
Oxervate March 2022
Oxlumo March 2022
Spravato March 2022
Zokinvy March 2022
Zulresso March 2022
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Acne or Rosacea Select Topical Agents March 2022
C5 Complement Inhibitors March 2022
CFTR Modulators March 2022
Fabry Disease March 2022
Givlaari March 2022
Isturisa March 2022
Scenesse March 2022
Sickle Cell Disease March 2022
Systemic Antifungals March 2022
Tavneos March 2022
Voxzogo March 2022
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents Topical March 2022
Androgenic Agents March 2022
Antibiotics Inhaled March 2022
Antifungals Topical March 2022
Antihistamines and Antihistamine-Decongestant Combos 2nd Gen March 2022
Antihistamines Intranasal March 2022
Antivirals Topical March 2022
Benzoyl Peroxide Antibiotic Combos March 2022
Corticosteriods Oral Inhaled March 2022
Corticosteroids and Rhinitis Agents Intranasal March 2022
Corticosteroids Topical March 2022
Cough Cold Preparation March 2022
Epinephrine Agents Self Injectable March 2022
Fluoroquinolones Ophthalmic March 2022
Fluoroquinolones Otic March 2022
Glaucoma Agents March 2022
Mast Cell Stabilizers Ophthalmic March 2022
NSAIDS Ophthalmic March 2022
Psoriasis Agents Oral March 2022
Psoriasis Agents Topical March 2022
Retinoids Topical March 2022
Ulcerative Colitis Agents Oral March 2022
Ulcerative Colitis Agents Rectal March 2022
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticholinergics LABAs ICS Combos and PDE4 Inhibitors March 2022
Anticholinergics Long Acting Beta Adrenergics Combos March 2022
Anticholinergics Long Acting Inhaled March 2022
Anticholinergics Short Acting and Combos Inhaled March 2022
Antifungals Oral March 2022
Antihistamines Ophthalmic March 2022
Antiparasitics Topical March 2022
Atopic Dermatitis Agents Immunomodulators March 2022
Beta Adrenergic Agents Short Acting March 2022
Beta Adrenergic Agents Long Acting March 2022
Beta Adrenergic Agents Nebulized March 2022
Corticosteroids Ophthalmic Soft March 2022
Hepatitis C Agents March 2022
Leukotriene Receptor Modifiers March 2022
Pancreatic Enzymes March 2022
Respiratory Monoclonal Antibodies March 2022

January 19, 2022

DUR Agenda January 2022
DUR Minutes January 2022
DUR Criteria
Conduent Reports
Media
Conduent Reports December 2021
DUR Criteria
Opioid Policy Review Edits
Media
High Risk Therapies December 2021
MHD Opioid Policy Update December 2021
MME December 2021
Oxandrin September 2021
Opioid Emergency Reversal Agents December 2021
Opioids Long Acting December 2020
Opioid Short Acting December 2021
TIRF December 2021
Tramadol Like Agents December 2021
DUR Criteria
PDL Proposals - No New Criteria
Media
Alzheimers Agents December 2021
Anticonvulsants Dravet Syndrome December 2021
Antiemetics THC Derivatives December 2021
Anti Parkinsonism MAO B Inhibitors December 2021
Anti Parkinsonism Non Ergot Dopamine Agonists December 2021
GI Motility Agents Chronic December 2021
Somatostatin Analogs December 2021
DUR Criteria
PDL Proposals - New Revised Criteria
Media
Antiandrogenic Agents December 2021
DUR Criteria
Clinical Edits - No New Criteria

2021

October 20, 2021

DUR 08-20-21 Agenda
DUR minutes 10-20-2021
DUR Criteria
Conduent Reports
Media
Conduent Reports September 2021
DUR Criteria
Preferred Drug List Proposals - No New Criteria
Media
Angiotensin Receptor Blocker Combo September 2021
Angiotensin Receptor Blocker CCB Combo September 2021
Beta Adrenergic Blocker Diuretic Combo September 2021
CCB Dihydropyridines September 2021
CCB Non Dihydropyridine September 2021
Direct Renin Inhibitors September 2021
Dry Eye Disease Agents September 2021
Niacin Derivatives September 2021
PAH Agents ETRAs September 2021
PAH Agents ETRAs September 2021
PAH Agents Prostacylin Pathway Agonists Inhaled September 2021
PAH Agents Prostacyclin Pathway Agonists Oral September 2021
Sympatholytic Agents September 2021
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
ACEI and ACEI Diuretic Combo September 2021
ACEI CCB Combos September 2021
ADHD Methylphenidate Long Acting September 2021
ADHD Methylphenidate Short Acting September 2021
ADHD Amphetamines Short Acting September 2021
ADHD Amphetamines Long Acting September 2021
ADHD Non Stimulant Agents September 2021
Anticoagulant Agents Oral and Subcutaneous September 2021
Anticonvulsants Rescue Agents September 2021
Antiplatelet Agents September 2021
Homozygous Familial Hypercholesterolemia Agents September 2021
PAH Agents PDE5 and SGC Stimulators September 2021
PAH Agents Prostacyclin Pathway Agonists Injectable September 2021
PCSK9 Inhibitors September 2021
Proton Pump Inhibitors September 2021
Statins and Combinations September 2021
Triglyceride Lowering Agents September 2021
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Emsam September 2021
Immunoglobulins September 2021
Lambert Eaton Myasthenic Syndrome September 2021
Neuromyelitis Optica Spectrum Disorder September 2021
Nuedexta September 2021
Oxandrin September 2021
Palforzia September 2021
Ranexa September 2021
Transthyretin Mediated Amyloidosis September 2021
Xcopri September 2021
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Aduhelm September 2021
Botulinum Toxin September 2021
Equetro September 2021
Narcolepsy Inhibitors September 2021
Psychotropic Medications Polypharmacy September 2021
Serotonin and Norepinephrine Reuptake Inhibitors September 2021
Selective Serotonin Reuptake Inhibitor September 2021

July 21, 2021

DUR 07-21-21 Agenda
DUR minutes 7-21-2021
DUR Criteria
Conduent Reports
Media
Conduent Reports June 2021
CyberAccess User Statistics June 2021
DUR Criteria
Preferred Drug List Proposals - No New Criteria
Media
Amylin Analogs June 2021
Antibiotic Vaginal June 2021
Bile Salt Agents June 2021
Cephalosporin Agents June 2021
Electrolyte Depleting Agents Phosphate Lowering June 2021
Electrolyte Depleting Agents Potassium Lowering June 2021
Fluoroquinolone Agents Oral June 2021
Insulin Mixed June 2021
Insulin Non Analogs June 2021
Penicillin Agents June 2021
Sulfonylurea Agents Second Generation June 2021
Targeted Immune Modulators IL6 Receptor Inhibitors June 2021
Thrombocytopenia Agents June 2021
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Alpha Glucosidase Inhibitors June 2021
Antibiotics GI Oral June 2021
Antibiotics Mupirocin Topical June 2021
Antihyperuricemic Agents June 2021
Benign Prostatic Hyperplasia Agents June 2021
Biguanides June 2021
Bone Ossification Agents June 2021
Colony Stimulating Factors June 2021
Cryopyrin Associated Periodic Syndrome June 2021
DPPIV Inhibitor June 2021
Erythropoiesis Stimulating Agents June 2021
GLP 1 Agonists June 2021
Growth Hormone Agents Somatropin June 2021
Growth Hormone Releasing Factors Select Agents June 2021
Insulin Long Acting June 2021
Insulin Rapid Acting June 2021
LHRH GnRH Agents Non Oral June 2021
Macrolide Agents June 2021
Meglitinide Agents June 2021
Methotrexate Agents June 2021
Multiple Sclerosis Agents Injectable June 2021
Multiple Sclerosis Agents Oral June 2021
SGLT2 Inhibitors June 2021
Targeted Immune Modulators IL17 June 2021
Targeted Immune Modulators IL23 IL12 inhibitors June 2021
Targeted Immune Modulators JAK Inhibitors June 2021
Targeted Immune Modulators Select Agents June 2021
Targeted Immune Modulators TNF Inhibitors June 2021
Tetracycline Agents June 2021
Thiazolidinediones June 2021
Urinary Tract Antispasmodics June 2021
DUR Criteria
Clinical Edits - No New Criteria
Media
Ampyra June 2021
Elagolix June 2021
Gamifant June 2021
Koselugo June 2021
Luxturna June 2021
Oxervate June 2021
Reblozyl June 2021
Synagis June 2021
Tepezza June 2021
Tolvaptan June 2021
Zometa June 2021
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
CAR T Cell June 2021
Crysvita June 2021
DMD June 2021
Entresto June 2021
Extended Supply June 2021
HBV Nucleotide Analog June 2021
Imcivree June 2021
Iron Injectable June 2021
Nulibry June 2021
Oxazolidinone June 2021
Palynziq June 2021
PTH and Other Agents June 2021
Verquvo June 2021
Zokinvy June 2021

April 21, 2021

DUR Agenda 04-21-2021
DUR Minutes 4-21-2021 Approved
DUR Criteria
Conduent Reports
Media
MO User Statistics
DUR Criteria
Clinical Edit Proposals – No New Criteria
Media
Acne or Rosacea Select Topical Agents March 2021
Givlaari March 2021
Megestrol March 2021
Sickle Cell Disease March 2021
Zulresso March 2021
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
CFTR March 2021
Clobazam Agents March 2021
Fabry Disease March 2021
Nocturnal Polyuria March 2021
Opioids Single Agent Short Acting March 2021
Oxlumo March 2021
Spravato March 2021
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents Topical March 2021
Antifungals Oral March 2021
Antihistamines Intranasal March 2021
Antihistamines Decongestant Combos 2nd Gen March 2021
Antivirals Oral March 2021
Antivirals Topical March 2021
Benzoyl Peroxide Antibiotic Combinations March 2021
Beta Adrenergic Agents Long Acting March 2021
Beta Adrenergic Agents Nebulized March 2021
Cough Cold Preparations March 2021
Fluoroquinolones Ophthalmic March 2021
Mast Cell Stabilizers Ophthalmic March 2021
NSAIDS Ophthalmic March 2021
Pancreatic Enzymes March 2021
Psoriasis Agents Oral March 2021
Psoriasis Agents Topical March 2021
Retinoids Topical March 2021
Ulcerative Colitis Agents Rectal March 2021
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Androgenic Agents March 2021
Antibiotics Inhaled March 2021
Antifungals Topical March 2021
Antihistamines Ophthalmic March 2021
Antiparasitics Topical March 2021
Atopic Dermatitis Agents Immunomodulators March 2021
Beta Adrenergic Agents Short Acting March 2021
COPD Agents March 2021
Corticosteroids Inhaled March 2021
Corticosteroids Intranasal March 2021
Corticosteroids Ophthalmic Soft March 2021
Corticosteroids Topical March 2021
Epinephrine Agents Self Injectable March 2021
Fluoroquinolones Otic March 2021
Glaucoma Agents March 2021
Hepatitis C Agents March 2021
Hereditary Angioedema March 2021
Leukotriene Receptor Modifiers March 2021
Respiratory Monoclonal Antibodies March 2021
Ulcerative Colitis Agents Oral March 2021

January 20, 2021

DUR 01-20-2021 Agenda
DUR Minutes 01-20-2021 Approved
DUR Criteria
Conduent Reports
Media
FY21 Top 25 Drugs Quarterly Report December 2020
CyberAccess User Statistics December 2020
Helpdesk Status Report November 2020
Logging Table November 2020
New Drug Summary November 2020
DUR Criteria
Clinical Edit Proposals
Media
15 Day Supply December 2020
15 Day Supply Oral Oncology December 2020
Antipsychotics 1st Gen Typical December 2020
Antipsychotics 2nd Gen Atypical December 2020
APAP Accumulation December 2020
Benzodiazepines Select Oral December 2020
BiDil December 2020
Biosimilar vs Reference December 2020
Butalbital Combo without Codeine December 2020
Butalbital Combo Excessive Therapy December 2020
Car T Cell December 2020
Corlanor December 2020
Diabetic Supply Quantity December 2020
DMD December 2020
Entresto December 2020
High Cost Medication Kits December 2020
High Risk Therapies December 2020
Isturisa December 2020
MME December 2020
NMOSD December 2020
Non-Oral Contraceptives December 2020
Opioids Single Agent-Short Acting December 2020
Out of State Pharmacies December 2020
PolyPharm December 2020
PrEP December 2020
SMA December 2020
TIRF December 2020
DUR Criteria
Preferred Drug List Proposals
Media
Alzheimer’s Agents December 2020
Antiandrogenic Agents December 2020
Anticonvulsants, Dravet Syndrome December 2020
Antiemetic 5HT3 NK1 Other Non-Injectable Agents December 2020
Antiemetic 5HT3, NK1 Agents, Injectable December 2020
Antiemetic THC Derivative Agents December 2020
Anti-Migraine Alternative Oral Agents December 2020
Anti-Migraine 5HT1 Agents December 2020
Anti-Parkinsonism, MAO-B Inhibitor Agents December 2020
Anti-Parkinsonisms Non-Ergot Dopamine Agonists December 2020
Antiretroviral Reference Products December 2020
Calcitonin Gene-Related Peptide (CGRP) Inhibitors December 2020
CDK4-6 Inhibitors December 2020
Fibromyalgia Agents December 2020
GI Motility Agents December 2020
Glucagon Agents December 2020
Hereditary Angioedema December 2020
Neuropathic Pain December 2020
NSAID Agents December 2020
Opioid Dependence Agents December 2020
Opioids Long Acting December 2020
Opioid Emergency Reversal Agents December 2020
Sedative Hypnotics December 2020
Skeletal Muscle Relaxants December 2020
Somatostatic Analogs December 2020
Tramadol-Like Agents December 2020
VMAT2 Inhibitors December 2020

2020

October 21, 2020

DUR Agenda October 2020
DUR Minutes October 2020
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
ATTR September 2020
Botulinum Toxin September 2020
Elagolix September 2020
Emsam September 2020
Equetro September 2020
Fintepla September 2020
Immunoglobulin September 2020
LEMS September 2020
Narcolepsy Inhibitors September 2020
Nuedexta September 2020
Oxandrin September 2020
Palforzia September 2020
Ranexa September 2020
SNRI September 2020
SSRI September 2020
Uplizna September 2020
VMAT2 September 2020
Xcopri September 2020
Zometa September 2020
DUR Criteria
Conduent Reports
Media
Top 25 Drugs Quarterly Reports June 2020
Help Desk Status Report June 2020
Logging Table May 2020
MO User Statistics
New Drug Summary May 2020
DUR Criteria
Preferred Drug List Proposed Edits
Media
ACEI ACEI-DIURETIC Combos September 2020
ACEI CCB Combos September 2020
ADHD Amphetmaines Long Acting September 2020
ADHD Amphetmaines Short Acting September 2020
ADHD Methylphenidate Long Acting September 2020
ADHD Methylphenidate Short Acting September 2020
ADHD Non-Stimulants September 2020
Anticoagulants September 2020
Anticonvulsants Rescue Agents September 2020
Antiplatelets September 2020
ARB ARB Diuretic Combos September 2020
ARB CCB Combos September 2020
BB/BB Diuretic Combos October 2020
CCB DHP September 2020
CCB NDHP September 2020
Direct Renin inhibitors Combos September 2020
Dry Eye PDL September 2020
PDA HFHC September 2020
PDA Niacin Derivatives September 2020
PAH ETRAS September 2020
PAH PDE5 SCG September 2020
PAH Prostacyclins Inhaled September 2020
PAH Prostacyclins Injectable September 2020
PAH Prostacyclins Oral September 2020
PCSK9 Inhibitors October 2020
PPIs October 2020
Statins September 2020
Sympatholytics September 2020
Triglyceride Lowering Agents September 2020

July 15, 2020

DUR Agenda July 2020
DUR Criteria
Clinical and Fiscal Edits
Media
Ampyra Clinical Edit June 2020
Crysvita Clinical Edit June 2020
Diacomit Clinical Edit June 2020
Gamifant Clinical Edit June 2020
Iron Injectable Step Therapy Edit June 2020
Koselugo Clinical Edit June 2020
Luxturna Clinical Edit June 2020
Orilissa Clinical Edit June 2020
Oxervate Clinical Edit June 2020
Palynziq Clinical Edit June 2020
PTH and Bone Resorption Suppression Related Agents Clinical Edit June 2020
Reblozyl Clinical Edit June 2020
Synagis Clinical Edit June 2020
Tepezza Clinical Edit June 2020
Tolvaptan Clinical Edit June 2020
DUR Criteria
Preferred Drug List Proposed Edits
Media
Alpha Glucosidase Inhibitors PDL Edit June 2020
Amylin Analogs PDL Edit June 2020
Antibiotics Vaginal Agents PDL Edit June 2020
Antibiotics GI Oral Agents PDL Edit
Antihyperuricemic Agents PDL Edit June 2020
Anti-Migraine Agents Alternative Oral Agents PDL Edit June 2020
Biguanides & Combination Agents PDL
Bile Salt Agents PDL Edit June 2020
Bone Ossification Agents PDL Edit June 2020
BPH July 2020
CAPS Agents PDL Edit June 2020
Cephalsporins July 2020
Colony Stimulating Factors PDL Edit June 2020
DPPIV July 2020
Elect Depleters - Potassium Lowering July 2020
Elect Depleters - Phosphate Lowering July 2020
Erythropoiesis Stimulating Agents PDL Edit June 2020
Fluoroquinolones Oral PDL Edit June 2020
GH GHRF Select Agents July 2020
GH Somatropin Agents July 2020
GLP1 Receptor Agonists and Combination Agents PDL Edit June 2020
Hepatitis C Agents PDL Edit June 2020
Insulins Long Acting PDL Edit June 2020
Insulins Non-Analogs PDL Edit June 2020
Insulins Rapid Acting PDL Edit June 2020
Insulins Mixed PDL Edit June 2020
Macrolides PDL Edit June 2020
Meglitinides PDL Edit June 2020
Methotrexate Agents PDL Edit June 2020
Multiple Sclerosis Injectable Agents PDL Edit June 2020
Multiple Sclerosis Oral Agents PDL Edit June 2020
Penicillins PDL Edit June 2020
SGLT2 Inhibitors and Combination Agents PDL Edit June 2020
Sulfonylureas 2nd Generation PDL Edit June 2020
Tetracyclines PDL Edit June 2020
Thiazolidinediones and Combination Agents PDL Edit June 2020
Thrombocytopenia Agents PDL Edit June 2020
TIMS IL6 Receptor Inhibitors July 2020
TIMS IL17 July 2020
TIMS JAK Inhibitors July 2020
TIMS Select Agents July 2020
TIMS TNF Inhibitors July 2020
Urinary Tract Antispasmodics PDL Edit June 2020

April 15, 2020

DUR Agenda April 2020
DUR Criteria
Clinical Edits - No New Criteria
Media
Acne and Rosacea Select Topical Agents Step Therapy Edit March 2020
Clobazam Agents Clinical Edit March 2020
DMD Clinical Edit March 2020
Epidiolex Clinical Edit March 2020
Galafold Clinical Edit March 2020
Givlaari Clinical Edit March 2020
Megestrol Acetate Clinical Edit March 2020
Nocturnal Polyuria Clinical Edit March 2020
Reblozyl Clinical Edit March 2020
Sickle Cell Disease Clinical Edit March 2020
Spravato Clinical Edit March 2020
Systemic Antifungals Clinical Edit March 2020
DUR Criteria
Preferred Drug List Proposed Edits
Media
Actinic Keratosis Agents Topical PDL Edit March 2020
Androgenic Agents PDL Edit March 2020
Antibiotics - Inhaled Agents April 2020
Antifungal Agents Oral PDL Edit March 2020
Antifungal Agents Topicals PDL Edit March 2020
Antihistamines Intranasal PDL Edit March 2020
Antihistamines Ophthalmic PDL Edit March 2020
Antihistamines Decongestant Combinations Low Sedating 2nd Gen PDL Edit March 2020
Antiparasitic Agents Topical PDL Edit March 2020
Antivirals Herpes Oral PDL Edit March 2020
Antivirals - Topical PDL
Atopic Dermatitis Agents Immunomodulators PDL Edit March 2020
Benzoyl Peroxide Antibiotic Combinations PDL Edit March 2020
Beta Adrenergic Agents Long Acting PDL Edit March 2020
Beta Adrenergic Agents Nebulized PDL Edit March 2020
Beta Adrenergic Agents Short Acting PDL Edit March 2020
COPD Anticholinergic Agents PDL Edit March 2020
Corticosteroids Oral Inhaled PDL Edit March 2020
Corticosteroids Ophthalmic Soft Steroids PDL Edit March 2020
Corticosteroids Topical PDL Edit March 2020
Corticosteroids and Rhinitis Agents Intranasal PDL Edit March 2020
Cough and Cold Preparations PDL Edit March 2020
Epinephrine Self Injectable Agents PDL Edit March 2020
Fluoroquinolones Ophthalmic PDL Edit March 2020
Fluoroquinolones Otic PDL Edit March 2020
Glaucoma Agents PDL Edit March 2020
Leukotriene Modifiers PDL Edit March 2020
Mast Cell Stabilizers Ophthalmic PDL Edit March 2020
NSAIDs – Ophthalmic PDL
Pancreatic Enzyme Agents PDL Edit March 2020
Psoriasis Agents Oral PDL Edit March 2020
Psoriasis Agents Topical PDL Edit March 2020
Retinoids Topical PDL Edit March 2020
Ulcerative Colitis Agents Oral PDL Edit March 2020
Ulcerative Colitis Agents Rectal PDL Edit March 2020
DUR Criteria
Reports
Media
Top 25 Drugs Quarterly Reports March 2020
Help Desk Status Report June 2020
Logging Table August 2020
MO User Statistics
New Drug Summary August 2020

January 15, 2020

DUR Agenda January 2020
DUR Minutes January 2020

2019

October 16, 2019

DUR Agenda October 2019
DUR Minutes October 2019

July 17, 2019

DUR Agenda July 2019
DUR Minutes July 2019

2018

July 18, 2018

DUR Agenda July 2018
DUR Minutes July 2018

April 18, 2018

DUR Agenda April 2018
DUR Minutes April 2018

January 17, 2018

DUR Agenda January 2018
DUR Minutes January 2018

2017

October 18, 2017

DUR Agenda October 2017
DUR Minutes October 2017

July 19, 2017

DUR Agenda July 2017
DUR Minutes July 2017

April 19, 2017

DUR Agenda April 2017
DUR Minutes April 2017

January 18, 2017

DUR Agenda January 2017
DUR Minutes January 2017

2016

October 19, 2016

DUR Agenda October 2016
DUR Minutes October 2016

July 20, 2016

DUR Agenda July 2016
DUR Minutes July 2016

April 16, 2016

DUR Agenda April 2016
DUR Minutes April 2016

January 20, 2016

DUR Agenda January 2016
DUR Minutes January 2016